The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).
 
Mark Yarchoan
Consulting or Advisory Role - Eisai; Exelixis; Geneos
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
 
Qingfeng Zhu
No Relationships to Disclose
 
Jennifer N. Durham
Employment - AstraZeneca/MedImmune (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune (I)
 
Nicole Gross
No Relationships to Disclose
 
Soren Charmsaz
No Relationships to Disclose
 
James M. Leatherman
No Relationships to Disclose
 
Shu Zhang
No Relationships to Disclose
 
Aleksandra Popovic
No Relationships to Disclose
 
Matthew John Weiss
No Relationships to Disclose
 
Benjamin Philosophe
No Relationships to Disclose
 
Richard A. Burkhart
No Relationships to Disclose
 
William Burns
No Relationships to Disclose
 
Brad Wilt
No Relationships to Disclose
 
Elizabeth Sugar
No Relationships to Disclose
 
Elana J. Fertig
No Relationships to Disclose
 
Dan Laheru
No Relationships to Disclose
 
Robert A Anders
No Relationships to Disclose
 
Elizabeth M. Jaffee
Stock and Other Ownership Interests - ABMETA Therapeutics
Consulting or Advisory Role - Achilles Therapeutics; Adaptive Biotechnologies; Avidea Technologies; CStone Pharmaceuticals; Dragonfly Therapeutics; Genocea Biosciences; Incyte; Medically Home
Research Funding - Aduro Biotech; Amgen; Avidea Technologies; Bristol-Myers Squibb; Corvus Pharmaceuticals; Roche
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genocea Biosciences; Medically Home; MedImmune
Other Relationship - Dragonfly Therapeutics
 
Won Jin Ho
Patents, Royalties, Other Intellectual Property - Rodeo Therapeutics